Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment

The transcription factor NeuroD2 coordinates synaptic innervation and cell intrinsic properties to control excitability of cortical pyramidal neurons

(2016) Fading Chen et al.   JOURNAL OF PHYSIOLOGY-LONDON

Genome-wide target analysis of NEUROD2 provides new insights into regulation of cortical projection neuron migration and differentiation

(2015) Efil Bayam et al.   BMC GENOMICS

Cognitive impairment in schizophrenia: the great unmet need

(2015) Ralph Aquila et al.   CNS SPECTRUMS

Glutamate and dopamine in schizophrenia: An update for the 21st century

(2015) Oliver Howes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: A meta-analysis

(2015) Anthony O. Ahmed et al.   PSYCHIATRY RESEARCH

Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity

(2015) Martin T. Strassnig et al.   SCHIZOPHRENIA RESEARCH

COMT genotype and response to cognitive remediation in schizophrenia

(2015) Jean-Pierre Lindenmayer et al.   SCHIZOPHRENIA RESEARCH

Developing treatments for cognitive deficits in schizophrenia: The challenge of translation

(2014) JW Young et al.   JOURNAL OF PSYCHOPHARMACOLOGY

A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation

(2014) Rune A. Kroken et al.   Frontiers in Psychiatry

Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis

(2012) Jian-Ping Zhang et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Association Between BDNF Val66Met Polymorphism and Cognitive Performance in Antipsychotic-Naïve Patients with Schizophrenia

(2012) Weihong Lu et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Neurodevelopmental model of schizophrenia: update 2012

(2012) J L Rapoport et al.   MOLECULAR PSYCHIATRY

Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia

(2011) Carrie K Jones et al.   NEUROPSYCHOPHARMACOLOGY

A genome-wide quantitative trait loci scan of neurocognitive performances in families with schizophrenia

(2010) Y.-J. Lien et al.   GENES BRAIN AND BEHAVIOR

Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone

(2010) M. Riedel et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia

(2010) M. Riedel et al.   PHARMACOPSYCHIATRY

Lack of association between SNPs in the NEUROD2 gene and alcohol dependence in a German patient sample

(2010) Peter Zill et al.   PSYCHIATRY RESEARCH

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

A Genome Screen for Quantitative Trait Loci Influencing Schizophrenia and Neurocognitive Phenotypes

(2008) Laura Almasy et al.   AMERICAN JOURNAL OF PSYCHIATRY

Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics

(2008) Ilja Spellmann et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models

(2008) Athina Markou et al.   NEUROPSYCHOPHARMACOLOGY